NCT03684395 - Accessibility to New Drugs Versus SOC in Sweden | Biotech Hunter

Enrollment

68,056

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions

Anticoagulation

Interventions

DRUG

DOACs: Rivaroxaban, Dabigatran, Apixaban

Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection

DRUG

Standard of care (Warfarin)

Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection

Trial Locations (1)

Stockholm